Background: Many clinicians will defer antidepressant treatment in the context of active substance use due to concern that active substance use will interfere with depression treatment response. Although there is evidence to the contrary, less is known about how active substance use affects depression treatment among persons with HIV. The public health impact of research in this area is particularly significant given the known adverse effects of depression on HIV-related health outcomes. We explored the effect of active substance use on depression treatment using data from a randomized clinical trial of depression treatment in HIV-infected, homeless and marginally housed persons in San Francisco. Methodology: All participants were diagnosed with a depressive disorder and randomly assigned to either a referral to community mental health treatment (N=71) or directly observed therapy with fluoxetine (N=66). Assessments, conducted every three months over a nine-month period, included the Hamilton Rating Scale for Depression, the Beck Depression Inventory, and self-report of any alcohol, crack, cocaine, heroin, or methamphetamine use in the past 90 days. We fit multilevel mixed-effects linear regression models to estimate the effect of depression treatment on depressive symptom severity, stratified by any alcohol use or any drug use in the past 90 days. Results: The effect of fluoxetine treatment on depression symptom severity was statistically significant irrespective of alcohol use status (see Table). When stratified by drug use status, the effect of fluoxetine treatment on depression symptom severity was statistically significant only among drug non-users. The observed treatment responses were generally smaller among alcohol and drug users than among nonusers, but the interaction terms were not statistically significant. Conclusions: We found that antidepressant treatment reduces depression symptom severity among HIV-infected patients with depressive disorders irrespective of comorbid active substance use. Given prior work in this area, depression treatment among active substance users may also improve HIVrelated health outcomes. An important limitation of this study was that our measures of substance use were self-reported and did not assess the extent to which substance use was associated with clinically significant impairment. Future studies should be powered to examine the effect of problematic substance use on antidepressant treatment response.